Show Notes
This week's episode is in honour of Frank Beier, who recently passed away on July 18, 2025. Frank leaves behind a remarkable legacy through the impact he made in the field of osteoarthritis. In this previous episode (2021), he discussed the recent advances in osteoarthritis understanding with a particular emphasis on novel targets and epigenetics.
Despite the large prevalence of osteoarthritis, there is no clinically approved drug which provides a cure. Currently, drugs focus on relieving symptoms such as pain. Experiments done in the laboratory have provided insight on osteoarthritis onset and progression and will likely guide therapeutic development.
We know that osteoarthritis is a disease of the whole organ meaning that any of the tissues involved in the synovial joint can be affected. The interplay between the various cell types involved is complex and understanding the interactions between cartilage, bone and synovium may be critical to therapeutic development.
Skeletal development likely plays a very important role in predisposition to disease. Through the identification of serious pathologies such as various forms of dwarfism (what in medical terms are called chondrodysplasias) the role of transcription factors and epigenetics is increasing our understanding of disease genesis.The study of the epigenetics of OA - the mechanism by which the human genome alters it’s gene expression (without changing the primary DNA sequence) has provided valuable information on novel risk factors for the disease and are potential therapeutic targets for OA.
RESOURCES Journal articles Nuclear receptors as potential drug targets in osteoarthritis Interplay between genetics and epigenetics in osteoarthritis Recent developments in emerging therapeutic targets of osteoarthritis
CONNECT WITH US Twitter: @ProfDavidHunter @jointactionorg Email: [email protected] Website: www.jointaction.info/podcast
If you enjoyed this episode, don't forget to subscribe to learn more about osteoarthritis from the world's leading experts! And please let us know what you thought by leaving us a review! Hosted on Acast. See acast.com/privacy for more information.
More from Joint Action
On this special World Arthritis Day episode of Joint Action, we are bringing together some of the most moving moments from our patient stories series, where real people share what it is like to live with osteoarthritis, and more importantly, what they did about it.
Do supplements really help with osteoarthritis, or are we wasting our money? On this week's episode of Joint Action, Associate Professor Joanna Harnett and Dr Jocelyn Bowden join Professor David Hunter to cut through the noise on complementary medicines, exploring what the evidence actually shows and how to make informed decisions about supplement use for osteoarthritis.
What does it really mean to live with hand osteoarthritis, and how do you stay active and engaged in life when your hands are constantly painful? On this week's episode of Joint Action, Giovanna Lever joins Professor David Hunter to share her personal journey living with hand osteoarthritis, diagnosed at 45 after years of struggling with pain, and what it has meant for her work, travel, and family life.
Is platelet-rich-plasma (PRP) a game changer for osteoarthritis, or is the evidence still catching up with the hype? On this week's episode of Joint Action, Dr Hamish Osborne joins Professor David Hunter to cut through the noise on PRP exploring what the research currently shows, where the gaps in evidence lie, and how patients and clinicians can navigate the decision together.
Do your knees crack, pop, or creak when you move? On this week's episode of Joint Action, Associate Professor Danilo De Oliveira Silva joins Professor David Hunter to explain what those sounds actually mean, whether they are something to worry about, and what the research tells us about the relationship between noisy knees and osteoarthritis.